By Ashley Mitchell, Law Student and Dispensary Manager
President Trump is expected to issue an executive order directing the Department of Justice to finalize the federal rescheduling of marijuana, a move that has prompted questions about whether such an approach is legally sound. From a legal perspective, however, this pathway is not only defensible but firmly grounded in existing statutory authority and administrative practice.
The Controlled Substances Act gives the attorney general, and by delegation the Drug Enforcement Administration, the authority to add, remove, or transfer substances between schedules. That process is not legislative in nature; it is administrative. While the president cannot unilaterally rewrite the statute, he can direct executive agencies to prioritize, complete, or accelerate actions already authorized by law. An executive order that instructs the DOJ to issue a final rule on rescheduling fits squarely within that framework.
Importantly, this would not represent the start of a new process. The rescheduling review was initiated under the prior administration and has already moved through several procedural stages. An executive order directing the DOJ under Attorney General Pam Bondi to complete that review would be more accurately characterized as continuity of executive action rather than a circumvention of law. Courts have historically been deferential when an administration completes or modifies regulatory actions that were lawfully begun by its predecessor.
Concerns about legality often hinge on the misconception that rescheduling by executive action bypasses Congress. In reality, Congress delegated this authority decades ago when it enacted the Controlled Substances Act. That delegation has been repeatedly upheld by federal courts, including in cases involving controversial or politically sensitive substances. As long as the agency follows required procedures, including notice, justification, and reliance on scientific and medical evaluation, the action is well insulated from legal challenge.
From an administrative law standpoint, directing an agency to finalize a rule already in progress may actually reduce litigation risk. Abandoning or reversing the process would likely invite challenges under the Administrative Procedure Act, particularly if the record already supports rescheduling. Moving forward, by contrast, aligns agency action with the existing evidentiary record.
Critics may argue that rescheduling should be left to Congress, but that is a policy argument, not a legal one. Congress chose this system, and presidents of both parties have used executive authority to shape drug scheduling outcomes. In that context, a Trump executive order directing the DOJ to finalize rescheduling is not an overreach. It is an exercise of authority explicitly contemplated by federal law.
If implemented carefully, this approach would likely take effect quickly and withstand judicial review, providing regulatory clarity while remaining within the bounds of established legal precedent.
More articles from The Marijuana Herald can be found below.
